Abrocitinib (Cibinqo®) is indicated for the treatment of moderate-to-severe atopic dermatitis in adults aged 18 years and older who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||16/11/2021|
|Rapid review completed||23/12/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that abrocitinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.